Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | POLG | P54098 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937354 | 0.88 | FAP (0.52) | FAPCYP3A4SLC22A6FGFR1ABCB11 | |
| SCHEMBL2914387 | 0.85 | FAP (0.35) | FAPALDH1A1 | |
| SCHEMBL4274931 | 0.84 | FAP (0.51) | FAPCYP3A4SLC22A6FGFR1ABCB11 | |
| SCHEMBL2942704 | 0.82 | FAP (0.51) | FAPCYP3A4SLC22A6FGFR1ADORA2A | |
| SCHEMBL2913580 | 0.82 | CYP3A4 (0.50) | CYP3A4SLC22A6FGFR1ADORA2AADORA1 | |
| SCHEMBL2942702 | 0.81 | FAP (0.50) | FAPCYP3A4SLC22A6FGFR1ADORA2A | |
| SCHEMBL2913934 | 0.79 | FAP (0.50) | FAPCYP3A4SLC22A6FGFR1ABCB11 | |
| SCHEMBL3290251 | 0.75 | FGFR1 (0.60) | FAPCYP3A4SLC22A6FGFR1ABCB11 | |
| SCHEMBL4265957 | 0.75 | FAP (0.53) | FAPCYP3A4SLC22A6FGFR1ABCB11 | |
| SCHEMBL13328650 | 0.74 | CYP3A4 (0.48) | FAPCYP3A4SLC22A6FGFR1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358198-B1 | NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME | LG LIFE SCIENCES LTD (KR) | 2010-08-25 | — | — | EP | claimed |
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | LG LIFE SCIENCES LTD. (KR) | 2006-03-09 | — | — | US | claimed |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2004-04-01 | — | — | US | claimed |
| US-7723319-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2010-05-25 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | LG LIFE SCIENCES LTD. (KR) | 2006-03-09 | — | — | US | disclosed |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | PNP, TYMP, ENTPD5 | FAP 2508/4885CYP3A4 1213/4885SLC22A6 989/4885 |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | FAP 2016/4885CYP3A4 456/4885SLC22A6 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.